Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin
- 15 September 1984
Abstract
Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single‐agent 5‐fluorouracil. One partial response of 24 months was seen. Eleven patients were treated with single‐agent Adriamycin (doxorubicin) after progression on 5‐fluorouracil, and one partial response of 34 months was seen. It is concluded that 5‐fluorouracil has only minimal activity in diffuse malignant mesothelioma. Preliminary data suggest that Adriamycin has little activity as a second‐line agent.This publication has 10 references indexed in Scilit:
- Reporting results of cancer treatmentCancer, 1981
- Dose: A critical factor in cancer chemotherapyAmerican Journal Of Medicine, 1980
- Pleural Mesothelioma: Clinical Features and Therapeutic ImplicationsAnnals of Internal Medicine, 1977
- Dose response evaluation of adriamycin in human neoplasiaCancer, 1977
- A phase III study comparing the clinical utility of four regimens of 5-Fluorouracil.A preliminary reportCancer, 1977
- Chemotherapy of malignant diffuse mesotheliomaCancer, 1976
- Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.Thorax, 1976
- Chemotherapy of Malignant MesotheliomaOncology, 1974
- 5-Fluorouracil in Cancer: An Improved RegimenAnnals of Internal Medicine, 1970
- Diffuse pleural mesothelioma: A clinical and pathological studyRespiratory Medicine, 1970